Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 241 participants.

Also called NCT01087502

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 241 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01087502
  • EudraCT 2009-016971-31
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Finland, Israel, Japan, New Zealand, Slovakia, Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01087502. Randomized; double masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2012-05 (actual). Results posted on 2013-10-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Glimepiride
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Linagliptin
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01087502
Content hash
ce36eea334f073684e77023bd93844142a1ed1f79f17b33e5b140e5e74deb2f8